Survodutide (BI 456906)
Obesity
Key Facts
About Zealand Pharma
Zealand Pharma's mission is to develop transformative peptide-based medicines that address the root causes of metabolic and gastrointestinal diseases, aiming to increase healthspan rather than merely treat symptoms. The company has achieved significant validation through strategic partnerships with major pharmaceutical players and has built a robust clinical pipeline anchored by its dual and triple agonists for obesity. Its strategy combines internal R&D excellence with selective collaborations to accelerate development and maximize global commercial reach.
View full company profileAbout Zealand Pharma
Zealand Pharma's mission is to develop transformative peptide-based medicines that address the root causes of metabolic and gastrointestinal diseases, aiming to increase healthspan rather than merely treat symptoms. The company has achieved significant validation through strategic partnerships with major pharmaceutical players and has built a robust clinical pipeline anchored by its dual and triple agonists for obesity. Its strategy combines internal R&D excellence with selective collaborations to accelerate development and maximize global commercial reach.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |